Determinants of specificity in coagulation proteases

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 11, 2005, Pages 2401-2408

  Page, M J ^a   Macgillivray, R T A ^b   Di Cera, E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Allostery; Exosite; Na+ binding; Serine protease; Substrate specificity

Indexed keywords

ACTIVATED PROTEIN C; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9A; CHYMOTRYPSIN; KALLIKREIN; SERINE PROTEINASE; SODIUM ION; THROMBIN; VENOMBIN A; VITAMIN K GROUP;

ALLOSTERISM; BLOOD CLOTTING; ENZYME SPECIFICITY; HYDROLYSIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW;

ALLOSTERIC REGULATION; AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; BLOOD COAGULATION; CATALYTIC DOMAIN; ENZYME ACTIVATION; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; PROTEIN FOLDING; SERINE ENDOPEPTIDASES; SODIUM; SUBSTRATE SPECIFICITY; THROMBIN;

EID: 28444470134     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01456.x     Document Type: Review

References (99)

1. Rawlings ND, Tolle DP, Barrett AJ. MEROPS: the peptidase database. Nucleic Acids Res 2004; 32(Database issue): D160-4.
2. Krem MM, Rose T, Di Cera E. The C-terminal sequence encodes function in serine proteases. J Biol Chem 1999; 274: 28063-6.
3. Rose T, Di Cera E. Substrate recognition drives the evolution of serine proteases. J Biol Chem 2002; 277: 19243-6.
4. Narayana SV, Carson M, el-Kabbani O, Kilpatrick JM, Moore D, Chen X, Bugg CE, Volanakis JE, DeLucas LJ. Structure of human factor D. A complement system protein at 2.0 A resolution. J Mol Biol 1994; 235: 695-708.
5. Pereira PJ, Bergner A, Macedo-Ribeiro S, Huber R, Matschiner G, Fritz H, Sommerhoff CP, Bode W. Human beta-tryptase is a ring-like tetramer with active sites facing a central pore. Nature 1998; 392: 306-11.
6. Dang QD, Di Cera E. Residue 225 determines the Na(+)-induced allosteric regulation of catalytic activity in serine proteases. PYOC Natl Acad Sci USA 1996; 93: 10653-6.
7. Dang OD, Vindigni A, Di Cera E. An allosteric switch controls the procoagulant and anticoagulant activities of thrombin. Proc Natl Acad Sci USA 1995; 92: 5977-81.
8. Krem MM, Di Cera E. Molecular markers of serine protease evolution. EMBO J 2001; 20: 3036-45.
9. Schechter I, Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967; 27: 157-62.
10. Ahmad SS, London FS, Walsh PN. The assembly of the factor X-activating complex on activated human platelets. J Thromb Haemost 2003; 1: 48-59.
11. Rezaie AR. Exosite-dependent regulation of the protein C anticoagulant pathway. Trends Cardiovasc Med 2003; 13: 8-15.
12. Harris JL, Backes BJ, Leonetti F, Mahrus S, Ellman JA, Craik CS. Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. Proc Natl Acad Sci USA 2000; 97: 7754-9.
13. Hedstrom L. Serine protease mechanism and specificity. Chem Rev 2002; 102: 4501-24.
14. Ross J, Jiang H, Kanost MR, Wang Y. Serine proteases and their homologs in the Drosophila melanogaster genome: an initial analysis of sequence conservation and phylogenetic relationships. Gene 2003; 304: 117-31.
15. Terado T, Nonaka MI, Nonaka M, Kimura H. Conservation of the modular structure of complement factor I through vertebrate evolution. Dev Comp Immunol 2002; 26: 403-13.
16. Mattler LE, Bang NU. Serine protease specificity for peptide chromogenic substrates. Thromb Haemost 1977; 38: 776-92.
17. Perona JJ, Hedstrom L, Rutter WJ, Fletterick RJ. Structural origins of Substrate discrimination in trypsin and chymotrypsin. Biochemistry 1995; 34: 1489-99.
18. Prasad S, Cantwell AM, Bush LA, Shih P, Xu H, Di Cera E. Residue Asp-189 controls both substrate binding and the monovalent cation specificity of thrombin. J Biol Chem 2004; 279: 10103-8.
19. Vindigni A, Dang QD, Di Cera E. Site-specific dissection of substrate recognition by thrombin. Nat Biotechnol 1997; 15: 891-5.
20. Padmanabhan K, Padmanabhan KP, Tulinsky A, Park CH, Bode W, Huber R, Blankenship DT, Cardin AD, Kisiel W. Structure of human des(1-15) factor Xa at 2.2 A resolution. J Mol Biol 1993; 232: 947-66.
21. Hopfner KP, Brandstetter H, Karcher A, Kopetzki E, Huber R, Engh RA, Bode W. Converting blood coagulation factor IXa into factor Xa: dramatic increase in amidolytic activity identifies important active site determinants. EMBO J 1997; 16: 6626-35.
22. Gaboriaud C, Rossi V, Bally I, Arlaud GJ, Fontecilla-Camps JC. Crystal structure of the catalytic domain of human complement els: a serine protease with a handle. EMBO J 2000; 19: 1755-65.
23. Carvalho AL, Sanz L, Barettino D, Romero A, Calvete JJ, Romao MJ. Crystal structure of a prostate kallikrein isolated from stallion seminal plasma: a homologue of human PSA. J Mol Biol 2002; 322: 325-37.
24. Bode W, Turk D, Karshikov A. The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci 1992; 1: 426-71.
25. Rezaie AR, Esmon CT. Molecular basis of residue 192 participation in determination of coagulation protease specificity. Eur J Biochem 1996; 242: 477-84.
26. Hsu YC, Hamaguchi N, Chang YJ, Lin SW. The distinct roles that Gln-192 and Glu-217 of factor IX play in selectivity for macromolecular substrates and inhibitors. Biochemistry 2001; 40: 11261-9.
27. Guinto ER, Ye J, Le Bonniec BF, Esmon CT. Glu192->Gln substitution in thrombin yields an enzyme that is effectively inhibited by bovine pancreatic trypsin inhibitor and tissue factor pathway inhibitor. J Biol Chem 1994; 269: 18395-400.
28. Nikai T, Ohara A, Komori Y, Fox JW, Sugihara H. Primary structure of a coagulant enzyme, bilineobin, from Agkistrodon bilineatus venom. Arch Biochem Biophys 1995; 318: 89-96.
29. Komori Y, Nikai T, Ohara A, Yagihashi S, Sugihara H. Effect of bilineobin, a thrombin-like proteinase from the venom of common cantil (Agkistrodon bilineatus). Toxicon 1993; 31: 257-70.
30. Castro HC, Suva DM, Craik C, Zingali RB. Structural features of a snake venom thrombin-like enzyme: thrombin and trypsin on a single catalytic platform? Biochim Biophys Acta 2001; 1547: 183-95.
31. Remington SJ, Woodbury RG, Reynolds RA, Matthews BW, Neurath H. The structure of rat mast cell protease II at 1.9-A resolution. Biochemistry 1988; 27: 8097-105.
32. Esmon CT, Mather T. Switching serine protease specificity. Nat Struct Biol 1998; 5: 933-7.
33. Wang C, Wang F, Li M, Tang Y, Zhang JP, Gui LL, An XM, Chang WR. Structural basis for broad substrate specificity of earthworm fibrinolytic enzyme component A. Biochem Biophys Res Commun 2004; 325: 877-82.
34. Arosio D, Ayala YM, Di Cera E. Mutation of W215 compromises thrombin cleavage of fibrinogen, but not of PAR-1 or protein C. Biochemistry 2000; 39: 8095-101.
35. Pineda AO, Chen ZW, Caccia S, Cantwell AM, Savvides SN, Waksman G, Mathews FS, Di Cera E. The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket. J Biol Chem 2004; 279: 39824-8.
36. Rauh D, Klebe G, Sturzebecher J, Stubbs MT. ZZ made EZ: influence of inhibitor configuration on enzyme selectivity. J Mol Biol 2003; 330: 761-70.
37. Rauh D, Klebe G, Stubbs MT. Understanding protein-ligand interactions: the price of protein flexibility. J Mol Biol 2004; 335: 1325-41.
38. Gibbs CS, Coutre SE, Tsiang M, Li WX, Jain AK, Dunn KE, Laws VS, Mao CT, Matsumura SY, Mejza SY, Paborsky LR, Leung LLK. Conversion of thrombin into an anticoagulant by protein engineering. Nature 1995; 378: 413-6.
39. Chang YJ, Hamaguchi N, Chang SC, Ruf W, Shen MC, Lin SW. Engineered recombinant factor VII Q217 variants with altered inhibitor specificities. Biochemistry 1999; 38: 10940-8.
40. + binding to thrombin. J Biol Chem 2004; 279: 31842-53.
41. Kurth T, Grahn S, Thormann M, Ullmann D, Hofmann HJ, Jakubke HD, Hedstrom L. Engineering the S1′ subsite of trypsin: design of a protease which cleaves between dibasic residues. Biochemistry 1998; 37: 11434-40.
42. Rezaie AR, Olson ST. Contribution of lysine 60f to S1′ specificity of thrombin. Biochemistry 1997; 36: 1026-33.
43. O'Brien G, Quinsey NS, Whisstock JC, Pike RN. Importance of the prime subsites of the C1s protease of the classical complement pathway for recognition of substrates. Biochemistry 2003; 42: 14939-45.
44. Sichler K, Banner DW, D'Arcy A, Hopfner KP, Huber R, Bode W, Kresse GB, Kopetzki E, Brandstetter H. Crystal structures of uninhibited factor Vila link its cofactor and substrate-assisted activation to specific interactions. J Mol Biol 2002; 322: 591-603.
45. Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 2003; 23: 17-25.
46. Fenton II JW. Thrombin. Ann N Y Acad Sci 1986; 485: 5-15.
47. Dickinson CD, Kelly CR, Ruf W. Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor Vila. Proc Natl Acad Sci USA 1996; 93: 14379-84.
48. Ayala YM, Cantwell AM, Rose T, Bush LA, Arosio D, Di Cera E. Molecular mapping of thrombin-receptor interactions. Proteins 2001; 45: 107-16.
49. Pineda AO, Cantwell AM, Bush LA, Rose T, Di Cera E. The thrombin epitope recognizing thrombomodulin is a highly cooperative hot spot in exosite I. J Biol Chem 2002; 277: 32015-9.
50. Bartunik HD, Summers LJ, Bartsch HH. Crystal structure of bovine beta-trypsin at 1.5 A resolution in a crystal form with low molecular packing density. Active site geometry, ion pairs and solvent structure. J Mol Biol 1989; 210: 813-28.
51. Tsiang M, Jain AK, Dunn KE, Rojas ME, Leung LL, Gibbs CS. Functional mapping of the surface residues of human thrombin. J Biol Chem 1995; 270: 16854-63.
52. Xu H, Bush LA, Pineda AO, Caccia S, Di Cera E. Thrombomodulin changes the molecular surface of interaction and the rate of complex formation between thrombin and protein C. J Biol Chem 2004; 280: 7956-61.
53. Fuentes-Prior P, Iwanaga Y, Huber R, Pagila R, Rumennik G, Seto M, Morser J, Light DR, Bode W. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. Nature 2000; 404: 518-25.
54. Vu TK, Wheaton VI, Hung DT, Charo I, Coughlin SR. Domains specifying thrombin-receptor interaction. Nature 1991; 353: 674-7.
55. Myles T, Le Bonniec BF, Stone SR. The dual role of thrombin's anion-binding exosite-I in the recognition and cleavage of the protease-activated receptor 1. Eur J Biochem 2001; 268: 70-7.
56. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-64.
57. Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, Coughlin SR. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997; 386: 502-6.
58. Bianchini EP, Pike RN, Le Bonniec BF. The elusive role of the potential factor X cation-binding exosite-1 in substrate and inhibitor interactions. J Biol Chem 2004; 279: 3671-9.
59. Krishnaswamy S, Betz A. Exosites determine macromolecular substrate recognition by prothrombinase. Biochemistry 1997; 36: 12080-6.
60. Orcutt SJ, Krishnaswamy S. Binding of substrate in two conformations to human prothrombinase drives consecutive cleavage at two sites in prothrombin. J Biol Chem 2004; 279: 54927-36.
61. Betz A, Krishnaswamy S. Regions remote from the site of cleavage determine macromolecular substrate recognition by the prothrombinase complex. J Biol Chem 1998; 273: 10709-18.
62. Boskovic DS, Krishnaswamy S. Exosite binding tethers the macromolecular substrate to the prothrombinase complex and directs cleavage at two spatially distinct sites. J Biol Chem 2000; 275: 38561-70.
63. Olson ST, Chuang YJ. Heparin activates antithrombin anticoagulant function by generating new interaction sites (exosites) for blood clotting proteinases. Trends Cardiovasc Med 2002; 12: 331-8.
64. Gettins PG. Serpin structure, mechanism, and function. Chem Rev 2002; 102: 4751-804.
65. De Cristofaro R, De Candia E, Rutella S, Weitz JI. The Asp(272)-Glu(282) region of platelet glycoprotein Ibalpha interacts with the heparin-binding site of alpha-thrombin and protects the enzyme from the heparin-catalyzed inhibition by antithrombin III. J Biol Chem 2000; 275: 3887-95.
66. Nogami K, Zhou Q, Myles T, Leung LL, Wakabayashi H, Fay PJ. Exosite-interactive regions in the A1 and A2 domains of factor VIII facilitate thrombin-catalyzed cleavage of heavy chain. J Biol Chem 2005; 280: 18476-87.
67. Quinsey NS, Whisstock JC, Le Bonniec B, Louvain V, Bottomley SP, Pike RN. Molecular determinants of the mechanism underlying acceleration of the interaction between antithrombin and factor Xa by heparin pentasaccharide. J Biol Chem 2002; 277: 15971-8.
68. Neuenschwander PF. Exosite occupation by heparin enhances the reactivity of blood coagulation factor IXa. Biochemistry 2004; 43: 2978-86.
69. + and factor Va in the prothrombinase complex. J Biol Chem 2004; 279: 48262-9.
70. Krishnaswamy S. Exosite-driven substrate specificity and function in coagulation. J Thromb Haemost 2005; 3: 54-67.
71. Di Cera E. Thrombin: a paradigm for enzymes allosterically activated by monovalent cations. CR Biol 2004; 327: 1065-76.
72. Wells CM, Di Cera E. Thrombin is a Na(+)-activated enzyme. Biochemistry 1992; 31: 11721-30.
73. Rezaie AR, He X. Sodium binding site of factor Xa: role of sodium in the prothrombinase complex. Biochemistry 2000; 39: 1817-25.
74. Camire RM. Prothrombinase assembly and S1 site occupation restore the catalytic activity of FXa impaired by mutation at the sodium-binding site. J Biol Chem 2002; 277: 37863-70.
75. He X, Rezaie AR. Identification and characterization of the sodium-binding site of activated protein C. J Biol Chem 1999; 274: 4970-6.
76. + site in the protease domain of human activated protein C (APC). Sodium ion in the APC crystal structure is coordinated to four carbonyl groups from two separate loops. J Biol Chem 2002; 277: 28987-95.
77. + binding site of thrombin. J Biol Chem 1995; 270: 22089-92.
78. Perona JJ, Craik CS. Evolutionary divergence of substrate specificity within the chymotrypsin-like serine protease fold. J Biol Chem 1997; 272: 29987-90.
79. + binding site of thrombin. Biophys Chem 1997; 63: 185-200.
80. Guinto ER, Di Cera E. Large heat capacity change in a protein-monovalent cation interaction. Biochemistry 1996; 35: 8800-4.
81. + binding to coagulation serine proteases. Biophys Chem 2001; 90: 89-96.
82. Degen SJ, McDowell SA, Sparks LM, Scharrer I. Prothrombin Frankfurt: a dysfunctional prothrombin characterized by substitution of Glu-466 by Ala. Thromb Haemost 1995; 73: 203-9.
83. Miyata T, Aruga R, Umeyama H, Bezeaud A, Guillin MC, Iwanaga S. Prothrombin Salakta: substitution of glutamic acid-466 by alanine reduces the fibrinogen clotting activity and the esterase activity. Biochemistry 1992; 31: 7457-62.
84. Henriksen RA, Dunham CK, Miller LD, Casey JT, Menke JB, Knupp CL, Usala SJ. Prothrombin Greenville, Arg517->Gln, identified in an individual heterozygous for dysprothrombinemia. Blood 1998; 91: 2026-31.
85. Sun WY, Smirnow D, Jenkins ML, Degen SJ. Prothrombin Scranton: substitution of an amino acid residue involved in the binding of Na (LYS-556 to THR) leads to dysprothrombinemia. Thromb Haemost 2001; 85: 65l-4.
86. Dang QD, Guinto ER, Di Cera E. Rational engineering of activity and specificity in a serine protease. Nat Biotechnol 1997; 15: 146-9.
87. Gruber A, Cantwell AM, Di Cera E, Hanson SR. The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo. J Biol Chem 2002; 277: 27581-4.
88. Mann KG. Thrombin formation. Chest 2003; 124(3 Suppl): 4S-10S.
89. Adrogue HJ, Madias NE. Hypernatremia. N Engl J Med 2000; 342: 1493-9.
90. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000; 342: 1581-9.
91. Di Cera E. Thrombin interactions. Chest 2003; 124(3 Suppl): 11S-7S.
92. Grant PJ, Tate GM, Hughes JR, Davies JA, Prentice CR. Does hypernatraemia promote thrombosis? Thromb Res 1985; 40: 393-9.
93. + concentration. Biochemistry 1995; 34: 9277-81.
94. Krem MM, Di Cera E. Evolution of enzyme cascades from embryonic development to blood coagulation. Trends Biochem Sci 2002; 27: 67-74.
95. Hedstrom L, Szilagyi L, Rutter WJ. Converting trypsin to chymotrypsin: the role of surface loops. Science 1992; 255: 1249-53.
96. Hedstrom L, Perona JJ, Rutter WJ. Converting trypsin to chymotrypsin: residue 172 is a substrate specificity determinant. Biochemistry 1994; 33: 8757-63.
97. Hung SH, Hedstrom L. Converting trypsin to elastase: substitution of the S1 site and adjacent loops reconstitutes esterase specificity but not amidase activity. Protein Eng 1998; 11: 669-73.
98. Venekei I, Szilagyi L, Graf L, Rutter WJ. Attempts to convert chymotrypsin to trypsin. FEBS Lett 1996; 383: 143-7.
99. Cantwell AM, Di Cera E. Rational design of a potent anticoagulant thrombin. J Biol Chem 2000; 275: 39827-30.